Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Gross Working Capital 5 year CAGR for the Trailing 12 Months (TTM) ending January 31, 2024: -21.56%

Kalvista Pharmaceuticals Inc Gross Working Capital 5 year CAGR is -21.56% for the Trailing 12 Months (TTM) ending January 31, 2024, a -146.45% change year over year. Gross working capital is a financial metric that represents the amount of a company's current assets available to cover its current liabilities and short-term debt obligations. It is calculated by subtracting the sum of current liabilities and short-term debt from the total current assets of a company. Gross working capital provides insights into a company's short-term liquidity and its ability to meet its financial obligations in the near future. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Kalvista Pharmaceuticals Inc Gross Working Capital for the Trailing 12 Months (TTM) ending January 31, 2023 was USD 659.11 M, a -28.47% change year over year.
Kalvista Pharmaceuticals Inc Gross Working Capital for the Trailing 12 Months (TTM) ending January 31, 2022 was USD 921.51 M, a 242.37% change year over year.
Kalvista Pharmaceuticals Inc Gross Working Capital for the Trailing 12 Months (TTM) ending January 31, 2021 was USD 269.15 M, a -29.92% change year over year.
Kalvista Pharmaceuticals Inc Gross Working Capital for the Trailing 12 Months (TTM) ending January 31, 2020 was USD 384.08 M, a 36.14% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends